ArticleClinical rheumatology2026
Peripheral blood cell dynamics during biological therapy in axial spondyloarthritis: association between lymphocytosis and treatment response.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate longitudinal changes in absolute lymphocyte counts and derived hematological ratios during biological therapy in axSpA, to evaluate the relationship between lymphocytosis and treatment response, and to compare lymphocytosis rates between TNFi- and IL-17i-treated patients.
methodsThis retrospective cohort study included 125 axSpA patients receiving biological therapy at a tertiary rheumatology center. Absolute lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were evaluated at baseline and at 6, 12, and 24 months. Longitudinal changes were assessed using the Friedman test. Treatment response was defined as BASDAI50 achievement. Lymphocytosis was defined as an absolute lymphocyte count > 3.5 × 10⁹/L. Kaplan-Meier and logistic regression analyses were performed to evaluate time-to-lymphocytosis and identify independent predictors.
resultsAbsolute lymphocyte counts increased significantly during follow-up (p = 0.001), while platelet counts decreased (p = 0.001) and monocyte counts remained stable (p = 0.232). NLR, PLR, and MLR all decreased significantly (all p = 0.001). Lymphocytosis developed in 34.7% of patients and was significantly associated with BASDAI50 response (89.1% vs. 69.3%, p = 0.014). Lymphocytosis developed significantly less frequently in IL-17i than TNFi-treated patients (11.8% vs. 38.4%, p = 0.004). On multivariable analysis, biological therapy class was independently associated with lymphocytosis development (OR = 0.215, 95% CI 0.069-0.667, p = 0.008). Most lymphocytosis events occurred within the first 2 years of therapy.
conclusionBiological therapy in axSpA is associated with increasing lymphocyte counts and decreasing inflammatory hematologic ratios. Lymphocytosis was associated with BASDAI50 response, suggesting it may represent a hematological correlate of therapeutic efficacy. The significantly lower lymphocytosis rate in IL-17i-treated patients suggests differential class-specific effects on peripheral blood cell homeostasis. Key Points • Biological therapy in axSpA was associated with progressive increases in peripheral lymphocyte counts. • Lymphocytosis is significantly associated with BASDAI50 treatment response in axSpA. • IL-17i-treated patients develop lymphocytosis significantly less frequently than TNFi-treated patients. • Biological therapy class is independently associated with lymphocytosis development.
Indexed as
Identifiers
42675237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.